NCT05608837View on ClinicalTrials.gov

Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 26, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions
Uveitis Related Cystoid Macular EdemaCystoid Macular Edema, Postoperative
Interventions
DRUG

OCS-01

One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.

Trial Locations (8)

16507

Erie Retina Research, Erie

75075

Texas Retina Associates, Plano

78503

Valley Retina Institute P.A, McAllen

90095

Stein Eye Institute at UCLA, Los Angeles

90211

Retina Vitreous Associates Medical Group, Beverly Hills

92647

Retina Associates of Southern California, Huntington Beach

94303

Byers Eye Institute at Stanford, Palo Alto

02451

Massachusetts Eye Research and Surgery Institution, Boston

Sponsors

Collaborators (1)

Oculis
All Listed Sponsors
collaborator

Global Ophthalmic Research Center (GORC)

UNKNOWN

collaborator

Oculis

INDUSTRY

lead

Quan Dong Nguyen

OTHER

NCT05608837 - Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema | Biotech Hunter | Biotech Hunter